Sacubitril/valsartan, as a dual inhibitor of neprilysin and the angiotensin II (Ang II) receptor, strengthens the effect of ANP and mitigates the hyperfiltration and renal tubular injury in the animal models of early DKD (117). This evidence concerns the gene NPPA and diabetic kidney disease.